Outeiro, Tiago Fleming

Authors Chopra A, Xylaki M, Yin F, Castro-Hernández R, Merghani M, Grande V, Mollenhauer B, Fischer A, Outeiro TF Journal NPJ Parkinsons Disease Citation NPJ Parkinsons Dis. 2026 May 6. Abstract N6-methyladenosine (m6A) is the most abundant transcriptional modification in eukaryotic RNA, regulating RNA fate. While the functions of m6A

Authors Folarin RO, Olopade FE, Gilbert TT, Ladagu AD, Dos Santos PIP, Mustapha OA, Kpasham LZ, Outeiro TF, Olopade JO Journal Metabolic Brain Disease Citation Metab Brain Dis. 2026 Mar 12;41(1):52. Abstract Vanadium, an environmental pollutant, is closely associated with neurodegeneration, primarily through oxidative damage and chronic neuroinflammation. While chronic

Authors Flores-León M, Outeiro TF Journal Movement Disorders Citation Mov Disord. 2025 Dec 26. Abstract Neurodegenerative diseases are pathological states characterized by progressive alterations in brain homeostasis during aging. Synucleinopathies, including Parkinson’s disease and dementia with Lewy bodies, are defined neuropathologically by the accumulation of inclusions known as Lewy bodies

Authors Outeiro TF, Koss DJ Journal Movement Disorders Citation Mov Disord. 2025 Nov 26. Abstract Alpha-synuclein (aSyn), historically studied for its synaptic functions and central role in Lewy body pathology, is emerging as a protein with significant nuclear activities relevant to Parkinson’s disease (PD) and related synucleinopathies. Recent advances reveal

Authors Lázaro DF, Amen T, Gerhardt E, Song C, Burns R, Kruse N, Santos PI, Milovanovic D, Höglinger G, Mollenhauer B, Luk KC, Lee VM, Outeiro TF Journal NPJ Parkinsons Disease Citation NPJ Parkinsons Dis. 2025 Nov 20;11(1):326. Abstract Alpha-synuclein (aSyn) is an intrinsically disordered protein involved in phase separation

Authors Vasili E, König A, Al-Azzani M, Bosbach C, Gatzemeier LM, Thom S, Chegão A, Miranda HV, Steinem C, Erskine D, Outeiro TF Journal NPJ Parkinsons Disease Citation NPJ Parkinsons Dis. 2025 Oct 23;11(1):307. Abstract The risk of developing Parkinson’s disease (PD) is elevated in individuals with type 2 diabetes

Authors Brücke C, Al-Azzani M, Ramalingam N, Ramón M, Sousa RL, Buratti F, Zech M, Sicking K, Amaral L, Gelpi E, Chandran A, Agarwal A, Chaves SR, Fernández CO, Dettmer U, Lautenschläger J, Zweckstetter M, Busnadiego RF, Zimprich A, Outeiro TF Journal Molecular Neurodegeneration Citation Mol Neurodegener. 2025 Sep 26;20(1):98.

Authors Al-Azzani M, Weber S, Ramalingam N, Ramón M, Shvachiy L, Mestre G, Zech M, Sicking K, de Opakua AI, Jayanthi V, Amaral L, Agarwal A, Chandran A, Chaves SR, Winkelmann J, Trenkwalder C, Schwager M, Pauli S, Dettmer U, Fernández CO, Lautenschläger J, Zweckstetter M, Busnadiego RF, Mollenhauer B,

Authors Kumar NH, Kluever V, Kaufmann SV, Bergmann C, Mousaei K, Tomas M, Marrero MC, Chopra A, Hirose M, Pallas M, Sanfeliu C, Ibrahim SM, Fischer A, Outeiro TF, Urlaub H, Tchumatchenko T, Lopez Otin C, Fornasiero EF Journal BioRxiv Citation bioRxiv 2025.08.14.669896 Abstract Brain aging is a major risk

Authors Yalçin M, Grande V, Outeiro TF, Relόgio A Journal NPJ Parkinsons Disease Citation NPJ Parkinsons Dis. 2025 Jul 14;11(1):213. Abstract Parkinson’s Disease (PD) is a prevalent neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. This leads to hallmark motor features that include bradykinesia,